|Bid||257.01 x 1100|
|Ask||259.66 x 800|
|Day's Range||253.63 - 260.34|
|52 Week Range||221.47 - 286.72|
|Beta (5Y Monthly)||1.09|
|PE Ratio (TTM)||94.18|
|Forward Dividend & Yield||3.16 (1.24%)|
|Ex-Dividend Date||Mar 08, 2020|
|1y Target Est||N/A|
U.S. stocks gained for a fourth straight session on Thursday and Wall Street's main indexes hit record highs as concerns eased over the economic fallout from the coronavirus outbreak in China. China said it would halve additional tariffs levied against some U.S. goods, seen by analysts as a move to boost confidence after the fast-spreading coronavirus disrupted businesses and sparked broad market volatility. The Dow Jones Industrial Average rose 88.92 points, or 0.3%, to 29,379.77, the S&P 500 gained 11.09 points, or 0.33%, to 3,345.78 and the Nasdaq Composite added 63.47 points, or 0.67%, to 9,572.15.
The S&P 500 and Dow Jones Industrials indexes eased from their record highs on Thursday, as investors took a breather after a stellar run this week on waning worries about the economic damage from the coronavirus epidemic. Both indexes scaled new levels at the open as China said it would halve extra tariffs on some U.S. goods following hefty stimulus to support an economy hit by shutdowns and travel restrictions due to the virus outbreak.
Becton Dickinson (BDX) delivered earnings and revenue surprises of 0.76% and 1.23%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Shares of Becton Dickinson & Co. tumbled 11% in premarket trading, after the medical technology company reported fiscal first-quarter earnings that topped expectations but lowered its full-year outlook, as it continues to work with the U.S. Federal Drug Administration on its software remediation plan for the Alaris System. Net income for the quarter to Dec. 31 fell to $240 million, or 87 cents a share, from $562 million, or $2.05 a share, in the year-earlier period. Excluding non-recurring items, adjusted earnings per share came to $2.65, above the FactSet consensus of $2.63. Revenue rose 1.6% to $4.23 billion, topping the FactSet consensus of $4.18 billion. For fiscal 2020, the company now expects adjusted EPS of $11.90 to $12.10, below expectations of $12.58, and revenue growth of 1.5% to 2.5%, while the FactSet consensus of $18.03 billion implies 5.4% growth. The stock has rallied 14% over the past three months, while the S&P 500 has gained 8.4%.
Investing.com - Becton Dickinson (NYSE:BDX) reported on Thursday first quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A vaccine designed to combat severe acute respiratory syndrome (SARS) and technological advances in vaccine platforms are likely to quicken the time it will take to develop a vaccine for the novel coronavirus that has killed at least 132 people and sickened nearly 6,000.
In this article we are going to estimate the intrinsic value of Becton, Dickinson and Company (NYSE:BDX) by projecting...
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Today we're going to take a look at the well-established Becton, Dickinson and Company (NYSE:BDX). The company's stock...
It has been a fantastic year for equity investors as Donald Trump pressured Federal Reserve to reduce interest rates and finalized the first leg of a trade deal with China. If you were a passive index fund investor, you had seen gains of 31% in your equity portfolio in 2019. However, if you were an […]
This weekend's Barron's reveals what legendary stock picker Peter Lynch has to say about active investing, growth stocks and more. Other featured articles look at which of the decade's top performers still ...
The medical-technology company boasts solid prospects, despite some questions about its Lutonix drug-coated balloon, which accounts for just a sliver of its revenues.